You are about to leave the Clinical Value website now.


Empowering Healthcare Professionals to Combat Liver Cancer in Australia

Your Resource Hub for Early Detection and Effective Management

Welcome to our website dedicated to addressing the pressing issue of primary liver cancer in Australia. As the country’s fastest-growing cause of cancer death, primary liver cancer often eludes detection until it’s too late for the latest treatments to make a significant impact.

Consequently, Australia lags behind with a 22% 5-year survival rate 1, in stark contrast to Japan’s 58% 2. With the looming threat of non-viral MASLD (metabolic-associated steatotic liver diseases) such as obesity, type 2 diabetes, and fatty liver (steatosis), action is imperative.

Recent estimates suggest that up to one-third of Australians may have fatty liver disease 3, placing obese patients at risk of developing chronic liver disease. The question arises: do you know how to identify and assist these patients, potentially averting chronic liver disease and liver cancer?

This platform is tailored for healthcare professionals (HCPs), including specialists, GPs, and nurses, who regularly interact with individuals at high risk of hepatocellular carcinoma (HCC), such as those with cirrhosis or hepatitis B virus (HBV).

Our content (reviewed by an HCC multi-disciplinary panel) aims to equip you with the knowledge, practical guidance, and resources necessary to identify at-risk individuals early, manage modifiable risk factors, and ultimately reduce the incidence of HCC while improving early diagnosis.

Join us in our commitment to combat primary liver cancer by staying informed, proactive, and prepared to make a difference in the lives of those at risk of this devastating disease.


You May Also Like

27 June 2024

The implications of identifying and managing HCC surveillance patients in General Practice

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.